BMS bet looking good as Augtyro approved in ROS1-positive NSCLC

Bristol Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

The US pharma major acquired the oral therapy - a tyrosine kinase inhibitor (TKI) targeting ROS1 oncogenic fusions - from Turning Point Therapeutics (Nasdaq: TPTX) for $4.1 billion last year.

This approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective response rate and durable response.